BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garzon-Muvdi T, Theodros D, Luksik AS, Maxwell R, Kim E, Jackson CM, Belcaid Z, Ganguly S, Tyler B, Brem H, Pardoll DM, Lim M. Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma. Oncotarget 2018;9:20681-97. [PMID: 29755681 DOI: 10.18632/oncotarget.25061] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 De Waele J, Verhezen T, van der Heijden S, Berneman ZN, Peeters M, Lardon F, Wouters A, Smits ELJM. A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy. J Exp Clin Cancer Res 2021;40:213. [PMID: 34172082 DOI: 10.1186/s13046-021-02017-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Najafi M, Farhood B, Mortezaee K. Contribution of regulatory T cells to cancer: A review. J Cell Physiol 2019;234:7983-93. [PMID: 30317612 DOI: 10.1002/jcp.27553] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 16.8] [Reference Citation Analysis]
3 Teng CF, Wang T, Wu TH, Lin JH, Shih FY, Shyu WC, Jeng LB. Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model. Ther Adv Med Oncol. 2020;12:1758835920922034. [PMID: 32565925 DOI: 10.1177/1758835920922034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
4 Xun Y, Yang H, Kaminska B, You H. Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma. J Hematol Oncol 2021;14:176. [PMID: 34715891 DOI: 10.1186/s13045-021-01191-2] [Reference Citation Analysis]
5 De Leo A, Ugolini A, Veglia F. Myeloid Cells in Glioblastoma Microenvironment. Cells 2020;10:E18. [PMID: 33374253 DOI: 10.3390/cells10010018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
6 Fidanza M, Gupta P, Sayana A, Shanker V, Pahlke SM, Vu B, Krantz F, Azameera A, Wong N, Anne N, Xia Y, Rong J, Anne A, Skirboll S, Lim M, Wong AJ. Enhancing proteasomal processing improves survival for a peptide vaccine used to treat glioblastoma. Sci Transl Med 2021;13:eaax4100. [PMID: 34135109 DOI: 10.1126/scitranslmed.aax4100] [Reference Citation Analysis]
7 Desland FA, Hormigo A. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy. Int J Mol Sci 2020;21:E7358. [PMID: 33027976 DOI: 10.3390/ijms21197358] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
8 Zhang J, Chen Y, Chen K, Huang Y, Xu X, Chen Q, Huang C, Luo J, Lin X. IL-33 drives the antitumour effects of dendritic cells via upregulating CYLD expression in pulmonary adenocarcinoma. Artif Cells Nanomed Biotechnol 2019;47:1335-41. [PMID: 30964341 DOI: 10.1080/21691401.2019.1596926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Farhood B, Najafi M, Mortezaee K. Cancer‐associated fibroblasts: Secretions, interactions, and therapy. J Cell Biochem 2019;120:2791-800. [DOI: 10.1002/jcb.27703] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
10 Cocco C, Morandi F, Airoldi I. Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes. Cells 2021;10:927. [PMID: 33920505 DOI: 10.3390/cells10040927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Chan HY, Choi J, Jackson C, Lim M. Combination immunotherapy strategies for glioblastoma. J Neurooncol 2021;151:375-91. [PMID: 33611705 DOI: 10.1007/s11060-020-03481-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Najafi M, Goradel NH, Farhood B, Salehi E, Solhjoo S, Toolee H, Kharazinejad E, Mortezaee K. Tumor microenvironment: Interactions and therapy. J Cell Physiol. 2019;234:5700-5721. [PMID: 30378106 DOI: 10.1002/jcp.27425] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 17.8] [Reference Citation Analysis]
13 Adhikaree J, Moreno-Vicente J, Kaur AP, Jackson AM, Patel PM. Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma. Cells 2020;9:E263. [PMID: 31973059 DOI: 10.3390/cells9020263] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
14 Smith M, García-Martínez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists in cancer immunotherapy. Oncoimmunology 2018;7:e1526250. [PMID: 30524908 DOI: 10.1080/2162402X.2018.1526250] [Cited by in Crossref: 90] [Cited by in F6Publishing: 44] [Article Influence: 22.5] [Reference Citation Analysis]
15 Lehrer EJ, McGee HM, Peterson JL, Vallow L, Ruiz-Garcia H, Zaorsky NG, Sharma S, Trifiletti DM. Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases. Int J Mol Sci 2018;19:E3054. [PMID: 30301252 DOI: 10.3390/ijms19103054] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
16 Mooney J, Bernstock JD, Ilyas A, Ibrahim A, Yamashita D, Markert JM, Nakano I. Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma. World Neurosurg 2019;129:90-100. [PMID: 31152883 DOI: 10.1016/j.wneu.2019.05.205] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
17 Kelly WJ, Giles AJ, Gilbert M. T lymphocyte-targeted immune checkpoint modulation in glioma. J Immunother Cancer 2020;8:e000379. [PMID: 32051289 DOI: 10.1136/jitc-2019-000379] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
18 Lopez-Bujanda ZA, Chaimowitz MG, Armstrong TD, Foote JB, Emens LA, Drake CG. Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen. Oncoimmunology 2020;9:1809926. [PMID: 33457094 DOI: 10.1080/2162402X.2020.1809926] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Huang Y, Zhang Q, Lubas M, Yuan Y, Yalcin F, Efe IE, Xia P, Motta E, Buonfiglioli A, Lehnardt S, Dzaye O, Flueh C, Synowitz M, Hu F, Kettenmann H. Synergistic Toll-like Receptor 3/9 Signaling Affects Properties and Impairs Glioma-Promoting Activity of Microglia. J Neurosci 2020;40:6428-43. [PMID: 32631940 DOI: 10.1523/JNEUROSCI.0666-20.2020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Wu A, Lim M. The Challenges and Future of Immunotherapy for Gliomas. Cancer J 2021;27:371-8. [PMID: 34570451 DOI: 10.1097/PPO.0000000000000544] [Reference Citation Analysis]
21 Martikainen M, Essand M. Virus-Based Immunotherapy of Glioblastoma. Cancers (Basel) 2019;11:E186. [PMID: 30764570 DOI: 10.3390/cancers11020186] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 21.7] [Reference Citation Analysis]
22 Versteven M, Van den Bergh JMJ, Broos K, Fujiki F, Campillo-Davo D, De Reu H, Morimoto S, Lecocq Q, Keyaerts M, Berneman Z, Sugiyama H, Van Tendeloo VFI, Breckpot K, Lion E. A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches. Oncotarget 2018;9:27797-808. [PMID: 29963238 DOI: 10.18632/oncotarget.25591] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
23 Srivastava S, Jackson C, Kim T, Choi J, Lim M. A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials. Cancers (Basel) 2019;11:E537. [PMID: 30991681 DOI: 10.3390/cancers11040537] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
24 Sevenich L. Turning "Cold" Into "Hot" Tumors-Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers. Front Oncol 2019;9:163. [PMID: 30941312 DOI: 10.3389/fonc.2019.00163] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 13.7] [Reference Citation Analysis]
25 Pombo Antunes AR, Scheyltjens I, Duerinck J, Neyns B, Movahedi K, Van Ginderachter JA. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. Elife 2020;9:e52176. [PMID: 32014107 DOI: 10.7554/eLife.52176] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 21.5] [Reference Citation Analysis]
26 Wu A, Maxwell R, Xia Y, Cardarelli P, Oyasu M, Belcaid Z, Kim E, Hung A, Luksik AS, Garzon-Muvdi T, Jackson CM, Mathios D, Theodros D, Cogswell J, Brem H, Pardoll DM, Lim M. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment. J Neurooncol. 2019;143:241-249. [PMID: 31025274 DOI: 10.1007/s11060-019-03172-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 12.7] [Reference Citation Analysis]
27 Kumar S, Sarthi P, Mani I, Ashraf MU, Kang MH, Kumar V, Bae YS. Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH. Cells 2021;10:2250. [PMID: 34571899 DOI: 10.3390/cells10092250] [Reference Citation Analysis]
28 Singh K, Hotchkiss KM, Patel KK, Wilkinson DS, Mohan AA, Cook SL, Sampson JH. Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma. Cancers (Basel) 2021;13:5367. [PMID: 34771532 DOI: 10.3390/cancers13215367] [Reference Citation Analysis]
29 Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res 2021;171:105780. [PMID: 34302977 DOI: 10.1016/j.phrs.2021.105780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Liang P, Wang G, Liu X, Wang Z, Wang J, Gao W. Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy. Biomaterials 2021;264:120447. [PMID: 33069137 DOI: 10.1016/j.biomaterials.2020.120447] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Jackson CM, Choi J, Lim M. Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol 2019;20:1100-9. [PMID: 31358997 DOI: 10.1038/s41590-019-0433-y] [Cited by in Crossref: 105] [Cited by in F6Publishing: 114] [Article Influence: 35.0] [Reference Citation Analysis]
32 Song E, Mao T, Dong H, Boisserand LSB, Antila S, Bosenberg M, Alitalo K, Thomas JL, Iwasaki A. VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. Nature 2020;577:689-94. [PMID: 31942068 DOI: 10.1038/s41586-019-1912-x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 87] [Article Influence: 48.5] [Reference Citation Analysis]
33 Teng CF, Wang T, Shih FY, Shyu WC, Jeng LB. Therapeutic efficacy of dendritic cell vaccine combined with programmed death 1 inhibitor for hepatocellular carcinoma. J Gastroenterol Hepatol 2021;36:1988-96. [PMID: 33462840 DOI: 10.1111/jgh.15398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Fanelli GN, Grassini D, Ortenzi V, Pasqualetti F, Montemurro N, Perrini P, Naccarato AG, Scatena C. Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies. Genes (Basel) 2021;12:445. [PMID: 33804731 DOI: 10.3390/genes12030445] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
35 Li C, Deng H, Zhou Y, Ye Y, Zhao S, Liang S, Cai S, Lin J, Tang Y, Wu Y. Expression and clinical significance of CXC chemokines in the glioblastoma microenvironment. Life Sci 2020;261:118486. [PMID: 32976881 DOI: 10.1016/j.lfs.2020.118486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Rajani KR, Carlstrom LP, Parney IF, Johnson AJ, Warrington AE, Burns TC. Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. Front Oncol 2018;8:656. [PMID: 30854331 DOI: 10.3389/fonc.2018.00656] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
37 von Scheidt B, Wang M, Oliver AJ, Chan JD, Jana MK, Ali AI, Clow F, Fraser JD, Quinn KM, Darcy PK, Kershaw MH, Slaney CY. Enterotoxins can support CAR T cells against solid tumors. Proc Natl Acad Sci U S A 2019;116:25229-35. [PMID: 31767744 DOI: 10.1073/pnas.1904618116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
38 Choi J, Pant A, Medikonda R, Kim YH, Routkevitch D, Saleh L, Tong L, Chan HY, Nedrow J, Jackson C, Jackson C, Lim M. Sustained localized delivery of immunotherapy to lymph nodes reverses immunosuppression and increases long-term survival in murine glioblastoma. Oncoimmunology 2021;10:1940673. [PMID: 34290904 DOI: 10.1080/2162402X.2021.1940673] [Reference Citation Analysis]